Two-year data from RISE and RIDE studies of ranibizumab in diabetic macular oedema presented at conference

Area: News
BioSpace has reported on the 24-month results from the Phase III RIDE and RISE studies, which evaluated the efficacy and safety of ranibizumab (Lucentis) in the treatment of diabetic macular oedema (DMO).  These findings have been presented at the American Diabetes Association Annual Scientific Sessions.   RISE (n=377) and RIDE (n=382) are both 36-month, double-blind sham-controlled studies, in which participants were randomised to receive monthly injections of either 0.3mg ranibizumab (RISE n=125; RIDE n=125), 0.5mg ranibizumab (RISE n=125; RIDE n=127) or monthly sham injections (RISE n=127; (Read more...)

Full Story →